Shengnuo Biotech announced that as of December 12, 2025, shareholder Chuanfa Investment, Deputy General Manager Lu Changliang, and Director and Deputy General Manager Wang Xiaoli, the time range of their holdings reduction plans has expired. Chuanfa Investment reduced its holdings of 4025,841 shares, accounting for 2.5579%, 69,5737 shares, current holdings of 4.6899%, with a total reduction of 151 million yuan; Lu Changliang reduced his holdings by a total of 96575 shares, accounting for 0.0614%, uncompleted 4 shares; current holdings reduced by 0.1841%, with a total reduction of 3.981 million yuan; Wang Xiaoli reduced her holdings by a total of 211,640 shares, accounting for 0.1345%, uncompleted 36,3056 shares, current holdings reduced by 1.3261%, with a total reduction of 87.598 million yuan.

Shengnuo Biotech announced that as of December 12, 2025, shareholder Chuanfa Investment, Deputy General Manager Lu Changliang, and Director and Deputy General Manager Wang Xiaoli, the time range of their holdings reduction plans has expired. Chuanfa Investment reduced its holdings of 4025,841 shares, accounting for 2.5579%, 69,5737 shares, current holdings of 4.6899%, with a total reduction of 151 million yuan; Lu Changliang reduced his holdings by a total of 96575 shares, accounting for 0.0614%, uncompleted 4 shares; current holdings reduced by 0.1841%, with a total reduction of 3.981 million yuan; Wang Xiaoli reduced her holdings by a total of 211,640 shares, accounting for 0.1345%, uncompleted 36,3056 shares, current holdings reduced by 1.3261%, with a total reduction of 87.598 million yuan.